$BCYC News

Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate

Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

Bicycle Therapeutics' Zelenectide Pevedotin Plus Pembrolizumab Shows SOC-Comparable Response And Improved Safety Profile In Metastatic Urothelial Cancer Phase 2 Study

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

Bicycle Therapeutics Reveals Oral and Poster Presentations At The 2026 ASCO Annual Meeting

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026

Bicycle Therapeutics Issues Updates From Its EphA2 Pipeline At The American Association for Cancer Research (AACR) Annual Meeting 2026

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade

European Equities Traded in the US as ADRs Rise in Tuesday Trading

European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading

Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11

European Equities Traded in the US as American Depositary Receipts Rising Sharply in Wednesday Trading

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)